Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4709 | risankizumab Wiki | 1.00 |
| drug4654 | placebo for risankizumab Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D014456 | Ulcer NIH | 0.30 |
| D003092 | Colitis NIH | 0.30 |
| D003093 | Colitis, Ulcerative NIH | 0.30 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002583 | Colitis HPO | 0.30 |
| HP:0100279 | Ulcerative colitis HPO | 0.30 |
Navigate: Correlations HPO
There is one clinical trial.
Mechanically ventilated patients with coronavirus disease 2019 (COVID-19) have a mortality of 24-53%, in part due to distal mucopurulent secretions interfering with ventilation. Dornase alfa is recombinant human DNase 1 and digests DNA in mucoid sputum. Nebulized dornase alfa is FDA-approved for cystic fibrosis treatment. DNA from neutrophil extracellular traps (NETs) contributes to the viscosity of mucopurulent secretions. NETs are found in the serum of patients with severe COVID-19, and targeting NETs reduces mortality in animal models of acute respiratory distress syndrome (ARDS). Thus, dornase alfa may be beneficial to patients with severe COVID-19-acting as a mucolytic and targeting NETs.
Description: discharge from ICU will be determined from the enterprise health record reporting database
Measure: Number of participants discharged from the intensive care unit (ICU) Time: 2 monthsDescription: survival will be determined from the enterprise health record reporting database
Measure: Number of participants who survived COVID-19 Time: 2-4 monthsDescription: fraction of inspired oxygen requirements will be measured
Measure: Mean change in FiO2 Time: 2 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports